ContraVir Pharmaceuticals Selected to Present at Cavendish Global Health Impact Forum

EDISON, N.J., Nov. 5, 2014 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place November 10-13, 2014 at Oxford University in the UK.  The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.  To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. 

Michael Moffat, Cavendish co-founder and President explained, "With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence.  The quality and originality of ContraVir's research and scientific insights in antiviral therapies positions ContraVir to make a major contribution to the treatment of infectious diseases, in particular the long-lasting pain associated with herpes zoster, or shingles, which is an infection caused by reactivation of the varicella zoster virus (VZV)."

"We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach in the development of our lead asset, FV-100, a fast-acting, once-daily oral antiviral agent for the treatment of shingles and also our commitment to growing our pipeline by targeting additional opportunities to establish ContraVir as a multifaceted antiviral therapeutics company," said James Sapirstein, chief executive officer of ContraVir Pharmaceuticals. "We welcome the chance to interact with many of world's leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

Cavendish Global consists of more than 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.

About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. ContraVir's lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus (VZV). Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, famcyclovir, and valacyclovir, the FDA approved drug for treating shingles. Moreover, FV-100 has been shown to have a more rapid onset of antiviral activity in preclinical models, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels and with a better dosing regimen. Phase 1 trials of FV-100 in volunteers were successfully completed, as well as a Phase 2a clinical trial in shingles patients. ContraVir plans to conduct a Phase 2b trial in patients with shingles to further explore FV-100's potential to treat the long-lasting nerve pain typically associated with shingles. ContraVir was formed in May 2013 by Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) and spun off as an independent public company in January 2014. For more information, please visit www.contravir.com.

About Cavendish Global
Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; upcoming events include Oxford, UK (November 2014), London, UK (January 2015) and San Diego, US (late-spring 2015)

For more information: http://cavendishglobal.com

For further information, please contact:

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
[email protected]; (212) 375-2664

Claire Sodja (media)
[email protected]; (212) 375-2686

SOURCE ContraVir Pharmaceuticals, Inc.

Related Links

http://www.contravir.com